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Large prospective cohort studies are critical for identifying etiologic factors for disease, but they require substantial
long-term research investment. Such studies can be conducted as multisite consortia of academic medical centers,
combinations of smaller ongoing studies, or a single large site such as a dominant regional health-care provider. Still
another strategy relies upon centralized conduct of most or all aspects, recruiting through multiple temporary
assessment centers. This is the approach used by a large-scale national resource in the United Kingdom known
as the ‘‘UK Biobank,’’ which completed recruitment/examination of 503,000 participants between 2007 and 2010
within budget and ahead of schedule. A key lesson from UK Biobank and similar studies is that large studies are
not simply small studies made large but, rather, require fundamentally different approaches in which ‘‘process’’
expertise is as important as scientiﬁc rigor. Embedding recruitment in a structure that facilitates outcome determination,
utilizing comprehensive and ﬂexible information technology, automating biospecimen processing, ensuring broad
consent, and establishing essentially autonomous leadership with appropriate oversight are all critical to success.
Whether and how these approaches may be transportable to the United States remain to be explored, but their
success in studies such as UK Biobank makes a compelling case for such explorations to begin.
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Large prospective cohort studies are indispensable for
identifying etiologic factors for disease, buttheir largescope
requires substantial long-term research investments. Prospec-
tive cohort studies are often conducted as multisite consortia
of large academic medical centers, each responsible for re-
cruitment, examination, and follow-up of participants in its
geographic area. This was the model initially explored for
a prospective study of up to 1,000,000 Americans (1), but its
large anticipated costs present a substantial hurdle.
Other models include combining ongoing, smaller studies
to provide more immediate answers at potentially lower costs
(2,3),butexistingstudiesare oftenlimitedandvariableinthe
diversity of populations, exposures, and diseases ascertained;
standardization ofmethods;and adequacy of existing consent
and data access (4, 5). Large cohorts recruited at a single site,
often through a dominant regional health-care provider, rep-
resent another approach (6, 7). Still another strategy relies
upon centralized conduct of most or all aspects of the study,
although responsibility for individual study-wide aspects can
be distributed to collaborating centers (Figure 1) (8). This is
the approach used by a large-scale national resource in the
United Kingdom known as ‘‘UK Biobank’’ (9), initiated in
2004 to examine genetic and environmental risk factors for
complex diseases. Brieﬂy, UK Biobank issued mailed in-
vitations to about 9 million persons aged 40–69 years living
within 25 miles (40.23 km) from the 21 study assessment
centers and registered with the National Health Service in the
United Kingdom. More than 500,000 participants responded
to this invitation and were examined between April 2007 and
June 2010. Detailed questionnaire, interview, and measure-
ment data were obtained during the 2–3 hour baseline as-
sessment, and multiple samples of blood, saliva, and urine
werecollected(Table1).Repeatassessmentsonasubsample
of 20,000 participants will address regression-dilution bias,
859 Am J Epidemiol. 2012;175(9):859–866and health outcomes will be assessed primarily through
national health records.
The centralized model, which UK Biobank adopted after
rejecting a costly, decentralized approach, has enabled its
leaders to achieve exceptional efﬁciencies in recruitment,
assessment, and record linkage while retaining diversity in
demographics and exposures. Cohort recruitment was achieved
not only ahead of schedule but also within budget (roughly
$100 million for 503,000 participants), enabling substantial
enhancements to be added to the study protocol.
The evident success of the UK Biobank model may pro-
vide valuable lessons for the conduct of large-scale studies
Figure 1. Traditional distributed model contrasted with novel centralized model. In A (a traditional distributed model), the roles of collaborating,
typically academic, centers in distributed models include large numbers of tasks that could be located in one or more central units. Coordinating
centers in these models tend to be responsible for developing and implementing data collection and monitoring systems, training and certiﬁcation
standards for study staff, and the biospecimen repositories. In B (a novel centralized model), centralized models concentrate multiple study-wide
activities in one or more coordinating centers, with each potentially handling related clusters of activities. Assessment centers focus on participant
examination and transmission of data and specimens, and they are kept open only so long as they are productive. Successive waves of assessment
centers represented by an initial group of centers 1–6 are followed by a wave of centers 7–12, and so on.
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States. The National Institutes of Health thus convened
a symposium summarized in this paper, involving several
large studies (Table 2) (10), to 1) examine novel aspects of
the UK Biobank design and its strengths and weaknesses;
2) compare the UK Biobank approach with those of other
large studies; and 3) identify lessons learned in maximizing
the efﬁciencies of these studies.
OVERARCHING CONSIDERATIONS
Suggested characteristics of an optimal cohort study for
examining genetic and environmental inﬂuences on disease
have been described (Table 3) (1). Large size is a key com-
ponent, as relevant genetic variants and other risk exposures
may be uncommon and effect sizes are often modest (11).
These are not, however, simply small studies made large, as
the costs and inefﬁciencies in 100-fold expansionof a 5,000-
person, disease-speciﬁc cohort study are prohibitive. Large
studies require fundamentally different approaches in which
minimizing cost is a primary consideration and ‘‘process’’
expertise to maximize efﬁciency of high-throughput operations
is as important as scientiﬁc rigor. Modern industrial design
principles that identify and manage critical choke points
are essential to ensuring high throughput and maintaining
quality (12).
Decentralized models involving semipermanent research
centers can be expensive to maintain and can present chal-
lenges in standardization.Usingtemporary assessmentcenters
in a centralized model avoids the need to maintain remote
ofﬁces, staff, and laboratory capabilities. Centralized models
may providegreater overall control of costs, as well as agility
inrespondingtochangingsituationssuchasrelocatingunder-
performing sites or modifying suboptimal procedures. They
may thus free investigators to focus on science rather than
miring them in the operational concerns of their individual
sites.
Centralized models may also have drawbacks. The inherent
need to choose a speciﬁc population base and standardized
assessments for a very large, centralized cohort may limit
the questions that can be addressed. This contrasts with the
diverse approaches fostered by multiple independent studies
that can be a powerful force for improving methodology and
assessing the replicability of ﬁndings. In addition, the potential
for disenfranchising academic centers accustomed to oper-
ational leadership in their assigned geographic area may risk
losing critical scientiﬁc input from these groups. Special care
is also needed to involve community-based organizations and
to ensure that they feel local concerns are being addressed in
a centralized study design. Keeping them engaged in a cen-
tralized model requires signiﬁcant effort with frequent local
visits andcommunity meetings that includethe study leader-
ship. Being chosen as part of a major national effort can be
a source of considerable community pride, especially if it is
clear that community input is valued and implemented.
Experienced investigators may also have well-functioning
local recruitment systems and understanding of unique local
conditions that may require tailoring of methods. Approaches
for harnessing this expertise need careful attention, but they
might include engaging academic investigators in protocol
development and implementation or tasking individual aca-
demic centers with study-wide functions such as ensuring
diversity of participants, developing novel substudies, or
responding to queries through a participant call center.
Table 1. Components of UK Biobank, With Participant Recruitment between 2007 and 2010
Baseline Questionnaire Baseline Physical Measurements Follow-up and Future Measures
Sociodemographic Blood pressure Stored blood, urine, saliva
Family history Weight, body impedance Repeat baseline assessment
(20,000 participants)
Psychosocial Waist and hip circumferences Access national health records
Environmental Seated and standing heights d Death
Lifestyle Grip strength d Cancer
Cognitive function Spirometry d Hospitalizations
Health status Bone density d Primary care
Food frequency Mailed triaxial accelerometers
Internet-administered 24-hour dietary
questionnaire
Enhanced phenotyping (last
100,000–150,000 participants recruited)
d Hearing
d Vascular reactivity
d Visual acuity
d Refractive error
d Intraocular pressure
d Corneal biomechanics
d Optical coherence tomography
d Fitness assessment
Abbreviation: UK, United Kingdom.
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‘‘response rate’’ is pursued during recruitment. Nationally
representative surveys, such as the National Health and
Nutrition Examination Survey (NHANES) (13) and smaller
disease-speciﬁc studies such as the Cardiovascular Health
Study (14), serve important aims in providing population-
based estimates of disease prevalence and incidence. For
this purpose, they need representative population samples,
necessitating considerable expenditures to ensure high re-
sponse rates (15, 16). The limitations of an essentially vol-
unteer sample are well known, particularly the generally
healthier proﬁle, higher educational attainment, and greater
health consciousness of volunteers (17). This ‘‘healthy volun-
teer’’ effect can lead to underestimation of disease prevalence
and incidence, but its impact on relative risk estimates for
environmental and genetic factors is generally not impor-
tant (18, 19). Although high response rates are critical for
population-based estimates of disease incidence, preva-
lence, or mortality, a 10% or even 1% response rate may be
acceptable in certain situations, especially if the focus is on
risk associations and the base population is large enough to
capture a diversity of exposures and backgrounds. Results
from such studies can still be applicable to populations with
different distributions of these exposures, although this
cannot be proven but only assumed for exposures that
are unknown or unknowable. High response rates thus need
not be a driving factor scientiﬁcally or economically. For
these reasons, UK Biobank chose to emphasize diversity but
to de-emphasize response rates. It has accepted yields of
5%–10% while realizing substantial savings by not attempt-
ing to convert initial refusals, as conversion was not found to
be effective in pilot studies.
Other important cost determinants include method of as-
certainment (such as registry vs. household enumeration),
complexity of data collection, and follow-up methods (such
as active vs. passive). Choice among these is largely driven
by the scope and goals of a given study. Irrespective of these
choices, however, centralized approaches are likely to provide
the advantages described above, as evidenced by the marked
reductionsinUKBiobankcostswhenitshiftedtoacentralized
design while keeping other aspects constant.
RECRUITMENT
Embedding participant recruitment within a structure that
facilitates determination of study outcomes, such as an ex-
istingelectronicmedicalrecords system (20)orareimburse-
ment system (16), greatly simpliﬁes participant follow-up.
The Kaiser Research Program on Genes, Environment, and
Health (RPGEH), Marshﬁeld Clinical Personalized Medicine
Research Program (PMRP), UK Biobank, and Vanderbilt
University BioVU all recruit from their respective patient
registries, simplifying subsequent record linkage for follow-up.
As it can be challenging to use such information to address
research hypotheses, such data may need further review and
validation.
Centralizing the invitation and appointment system can
maximize efﬁciencies in recruitment and scheduling, allow-
ing study-wide monitoring of invitations sent, conﬁrmations
received, and appointments made. A centralized approach
also facilitates weekly or even daily monitoring of key char-
acteristics of participants study-wide; sampling fractions can
thenbemodiﬁedinrealtimetoincreaserecruitmentofunder-
subscribed groups.
Recognizing that participation rates tend to fall with in-
creased distance to an examination center, invitations can
be concentrated close to the center and extended gradually
Table 2. Large Studies Examined
Decentralized, Multisite Single Site Centrally Coordinated
Canadian Partnership for Tomorrow Kaiser Permanente Research Program on
Genes, Environment, and Health (RPGEH)
American Cancer Society Cancer
Prevention Study 3 (ACS CPS-3)
European Prospective Investigation into
Cancer and Nutrition (EPIC)
Marshﬁeld Clinic Personalized Medicine
Research Program (PMRP)
LifeGene
National Children’s Study Vanderbilt BioVU, a research resource providing
a ‘‘view into biology’’ at the level of DNA
National Health and Nutrition
Examination Survey (NHANES)
Prostate, Lung, Colorectal, and Ovarian
(PLCO) Cancer Screening Trial
UK Biobank
VA Genomic Medicine Program
Women’s Health Initiative
Abbreviation: UK, United Kingdom.
Table 3. Characteristics of Optimal Cohort Study
a
d Large in scale (hundreds of thousands of participants)
d Diverse regarding age, race/ethnicity, socioeconomic status,
geographic region
d Address multiple diseases/risk factors
d Highly efﬁcient recruitment, data collection, sample processing
d Standardized or harmonized terminology to facilitate
interoperability with other data
d Linked personal electronic records and biospecimens
d Broad content and high quality of samples and data
d State-of-the-art technology for environmental sampling,
laboratory methods, genomics, information technology
d Cost effective
d Data available for qualiﬁed researchers
a According to F. S. Collins (Nature. 2004;429(6990):475–477) (1).
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center and opening another in a new area (Web Figure 1,
posted on the Journal’s website (http://aje.oxfordjournals.
org/)). High-performing centers can also be kept open longer
than originally planned as long as they remain cost-effective
and provide sufﬁcient diversity in exposures and demograph-
ics. Optimal locations for assessment centers can be pinpointed
by mapping population density, transportation routes, and
available ofﬁce space. Establishing assessment centers where
and when they are needed, stafﬁng them primarily with tem-
porary personnel speciﬁcally trained for the needs of the pro-
ject, and closing them when they cease to meet recruitment
goalsprovideconsiderableefﬁcienciesoverestablishingaﬁxed
number of centers and keeping all of them open throughout the
recruitment period. Cost per participant recruited is a driving
force in the cost of these studies and should be a primary focus
in designing recruitment strategies, as long as fundamental
scientiﬁc goals remain paramount.
Novel approaches to recruitment include enrolling partic-
ipants at fund-raising events, such as the American Cancer
Society’s ‘‘Relay For Life’’ or through worksite recruitment
at corporate partners of such organizations. Yield of these
strategies can be low, however, particularly for certain demo-
graphic groups. Direct mail approaches may also introduce
some demographic biases becausewillingness to respond to,
or indeed even to open, mailed invitations varies consider-
ably. Even a 1% yield, however, as experienced in some US
studies (21), may be cost-effective if mailing is inexpensive
and there is a sufﬁciently large and diverse base population.
Internet and other social media approaches have potential
for even lower costs and are being explored in many studies,
but they do have pronounced differences by demographics;
this may abate over time as Internet use expands. Text mes-
saging for conﬁrmation of appointments, for example, has
proven to be effective with younger participants (22).
Another aspect that can be usefully centralized is respond-
ing to queries about the study. A single participant call center
can rapidly gain experience in responding to concerns effec-
tively and consistently, and it can also allow rapid escalation
to more senior staff as needed. In UK Biobank, for example,
roughly 50% of invitees calling to express concerns ultimately
participated, anddata on speciﬁc concernswereused tomodify
invitation materials and clinic ﬂow (23).
Sending invitees a provisional appointment (‘‘...an ap-
pointment has been scheduled for you on date/time; if you
would like to conﬁrm or change this optional appointment
please contact us ...’’) entails some risk, as they may view
it as presumptuous. It has, however, been used successfully
by some health services for their national screening programs,
such as National Health Service breast screening in the United
Kingdom. Like all other aspects of recruitment, it needs to be
carefully piloted, and its effectiveness may well vary by cul-
tural or demographic characteristics. Still, it was quite success-
ful in UK Biobank where roughly half of all participants who
attended did so at the time of their provisional appointments.
QUESTIONNAIRE AND EXAMINATION
Several studies, including the European Prospective Inves-
tigation into Cancer and Nutrition (EPIC), the US National
Health and Nutrition Examination Survey, and UK Biobank,
have recognized the efﬁciency of having participants re-
spond to questionnaires by touch screen rather than through
interviewer- or self-administered forms. Well-designed touch-
screensystemscanallowasinglestaffmembertoassist15–20
participants at a time. Electronic data capture in real time
m i n i m i z e se r r o r si nt r a n s c r i p tion, and ongoing analysis of
data quality can help to identify and correct problems early.
In addition, computerized instruments can be used to collect
more than questionnaire data, including tests of cognitive func-
tion, audiology, and simple motor function. Internet-based
24-hour dietary recalls administered remotely in UK Biobank,
for example, will permit more in-depth evaluation of intake
of total energy and some nutrients and will facilitate repeat
measurements.
BIOREPOSITORY
Biorepositories provide much of the future value of cohort
studies, as they permit measurement of biomarkers of expo-
sures or intermediate phenotypes often not even imagined at
the time the study is initiated. Central processing of biospeci-
mens typically offers increased consistency and achievable
throughput,a robust datatrail, andlowercosts comparedwith
local processing, although this must be piloted carefully in
each setting (12). Automated, industrial-scale specimen pro-
cessing and storage systems are indispensable in large studies
although their costs may make them impractical for smaller
studies. Implementation following best practices used in the
manufacturing industry can reduce project risk and build in
quality and robustness (12).
HEALTH OUTCOMES
Large-scale studies can examine a nearly unlimited number
of outcomes provided the outcomes can be classiﬁed reliably
Table 4. Key Lessons From New Models of Large Cohort Studies
n Ensure that future studies, including disease-speciﬁc studies,
address the widest possible range of outcomes to permit
combining data for increased study power
n Use standardized or harmonized (not identical but comparable)
measures to permit diverse studies to be combined
a
n Establish consents that allow for broad data sharing as the norm
n Maximize cost-efﬁciency where appropriate by
d Exploring centralized recruitment and examination models
d Considering lower recruitment yield if associations rather
than prevalence are the primary objective
d Utilizing electronic records
d Emphasizingindustrial-scaleprocessexpertiseasthe driver
of process organization, implementation, and monitoring
d Maximizing the capabilities of information technology to
ensure high-quality data, rapid transfer, and real-time
monitoring
d Phasing activities to be completed only shortly before they
are needed
a According to DataSHaPER (http://www.datashaper.org/) (30) and
C. M. Hamilton et al. (doi:10.1093/aje/kwr193) (31).
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outcome data is greatly facilitated by comprehensive elec-
tronic medical records; indeed, the feasibility of UK Biobank
was questioned before links with National Health Service
outcomes data were ﬁrmly established. Electronic medical
records can pose unique challenges, however, because they
often include complex and variable medical terminology,
may be difﬁcult to interpretwith regard to timing of measure-
ments, and cannot easily be reduced to common elements for
pooled analyses.
To the degree that standardized terminology can be ex-
tracted from electronic medical records, however, automated
algorithms can be developed and are being actively used
in programs such as the Marshﬁeld and Vanderbilt studies
(24, 25). Extending electronic systems of outcome assessment
to a national scale may be one of the greatest challenges to
implementing a truly nationwide US cohort study.
INFORMATION TECHNOLOGY
High-quality information technology systems arguably
represent the single most important infrastructure compo-
nent for ensuring high data quality and cost control in large
studies. Ideally, they should be designed to maximize par-
ticipant throughput, perform routine data quality checks, and
enable access and linkage to other data systems.
Real-time data capture and essentially daily review are
critical to the smooth operations of large-scale projects, as
the volume of data and potential errors identiﬁed through
less frequent monitoring could become overwhelming. Use
of commercial softwarewhen possible may be cost-effective,
particularly for routine components such as laboratory infor-
mation systems, but such systems must be interoperable with
other assessment center systems. Working within established
electronic medical record systems can facilitate leveraging
extensive infrastructures established for clinical care. Research
use of these systems may also facilitate further development
ofelectronicmedical records for researchand,potentially, for
direct incorporation of research ﬁndings into clinical care.
Threats to participant privacy may best be managed by
removing obvious identiﬁers and establishing user agreements
cosigned by an outside data user’s institution, with reliance
on professional standards of conduct to prevent misuse
(26). Minimizing reidentiﬁcation risk is an area of active
investigation (27).
CONSENT AND COMMUNITY CONCERNS
Maximizing the value of large-scale studies requires ready
access by a wide community of investigators for research
consistent with participants’ consent. Studies not requiring
a high recruitment yield can include broad data collection,
sharing, and use in their initial consent process and exclude
invitees uncomfortablewith these terms. Other studies may
allow multiple levels of consent designating permitted research
uses and data acquisition, and use can then be customized to
the level of consent. Funders of these studies also have a re-
sponsibility, and a clear interest, in maximizing the value
of the research investment by ensuring broad data sharing
within the constraints of participant privacy and consent.
Participants’ expectations for return of research results may
also need to be addressed (28).
External oversight helps to ensure that participants’ con-
cerns are voiced and addressed. Many such studies have
community advisory boards that meet regularly, while larger
studies may have more formally chartered and even nationally
recognized advisory groups such as UK Biobank’s indepen-
dent Ethics and Governance Council. Such groups essentially
‘‘hold up a mirror’’ to ongoing studies and provide valuable
input as well as wider credibility on issues such as privacy,
adherence to consent limitations, and ethics. Funders should
maintain some distance from ethics and governance issues,
yet cannot remain totally aloof, as large studies generally
carry the imprimatur of the funding organization and potential
lapses will often be laid at their door.
CONCLUSIONS AND POTENTIAL NEXT STEPS
That large prospective studies are not simply small studies
made large is a crucial consideration in successfully carrying
them out. The scale of these studies necessitates entirely dif-
ferent approaches, emphasizing cost-efﬁciency to a degree that
may appear inimical to the scientiﬁc method. In fact, it can
be indispensable to the science, enabling studies to go forward
that might otherwise be impossible. The £68 million (~$100
million) cost of developing and recruiting the UK Biobank
cohortover3yearsstandsinstarkcontrasttotheroughly$400
million per year for 10 years estimated for traditional models
of conducting a large cohort study in the United States (29).
Cohort studies, whether large or small, have much to learn
from and contribute to each other (Table 4). As all models
have their strengths and weaknesses, it is unwise to propose
from among them the one ‘‘best,’’ but better to recognize the
need for, and complementary nature of, a variety of designs
and approaches. Adoption of a large, centralized model for
one study should not, by virtue of its size and cost, have
a chilling effect on enthusiasm for and funding of other
complementary approaches.
Methods successfully used in European studies, such as the
European Prospective Investigation into Cancer and Nutrition,
LifeGene, and UK Biobank, may not all be directly transport-
able to the United States, where infrastructures for facilitating
follow-up on a national scale are limited andwhere diversity
in lifestyle, ancestral origin, and geography, as well as sheer
size, is considerably greater than in many other countries.
Careful piloting and critical evaluation will be needed to
assess the feasibility of such models in the United States.
The success to date of these models in studies such as
UK Biobank, however, makes a compelling case for such
explorations to begin.
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